Can two antibodies free HIV patients from daily pills? early trial launches
NCT ID NCT06987318
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests whether two lab-made antibodies can help people with HIV control the virus after stopping their regular antiretroviral therapy. The 40 participants all started HIV treatment very early after infection. Researchers will monitor safety and see if the antibodies keep virus levels low during a temporary break from daily medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Two human antibodies (VRC07-523LS and PGT121.414.LS) given by IV infusion
What this could lead to
If successful, this could point toward a way for some people with HIV to control the virus without daily medication, potentially reducing lifelong drug dependence.
What could go wrong
This is a very early Phase 1 trial with only 40 participants, so results may not apply broadly. The antibodies may not suppress the virus for long, and there are risks of side effects or the virus becoming resistant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35222, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Barranco CRS
Lima, 15063, Peru
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chapel Hill CRS
Chapel Hill, North Carolina, 27599-7215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Houston Advancing Research Team CRS
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Rio de Janeiro, 21040-900, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS
Porto Alegre, Rio Grande do Sul, 91350-180, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital CRS (MGH CRS)
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern University CRS
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University CRS
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Penn Therapeutics CRS
Philadelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308-2012, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCSD Antiviral Research Center CRS
San Diego, California, 92103, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Hospital CRS
Aurora, Colorado, 80045, United States
Contact Phone: •••-•••-••••